<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731832</url>
  </required_header>
  <id_info>
    <org_study_id>DSMM XV</org_study_id>
    <nct_id>NCT03731832</nct_id>
  </id_info>
  <brief_title>Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Pomalidomide, Ixazomib, and Dexamethasone (PId) With or Without Intensification by Cyclophosphamide (PICd): A Phase II Study in Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a multicenter, non-randomized, Phase II trial with one treatment&#xD;
      arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory&#xD;
      multiple myeloma are planned to be included in the study. After the first 6 patients will&#xD;
      have finished the first treatment cycle of the induction phase the DMC will assess safety and&#xD;
      tolerability of the treatment schedule and decide about the further continuation of the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as an open-label, non-randomized, multicenter study to investigate the&#xD;
      clinical activity of pomalidomide administered once daily in combination with oral ixazomib&#xD;
      and dexamethasone (PId) until disease progression according to IMWG criteria.&#xD;
&#xD;
      Patients with clinical relapse (any one of the following: deterioration of renal function,&#xD;
      hypercalcemia, newly developing osteolytic lesions and/or soft tissue plasmacytomas) will go&#xD;
      off study and receive further treatment according to their treating physician. Patients with&#xD;
      isolated biochemical relapse with an increase of serum M-protein of ≥ 25% (absolute increase&#xD;
      in serum must be ≥ 5 g/L) and/or urine M-protein (absolute increase in urine must be ≥ 200&#xD;
      mg/24h) or in the difference between involved and uninvolved FLC levels (provided, the&#xD;
      absolute increase is &gt; 100 mg/L) without further signs or symptoms will proceed to the&#xD;
      intensification phase (PICd).&#xD;
&#xD;
      The intensification phase (PICd) will last until further disease progression. In case of&#xD;
      significant haematological and non-haematological toxicities, dose adjustments and/or&#xD;
      interruption of the study drugs may be necessary.&#xD;
&#xD;
      Response assessments will be performed every four weeks by evaluation of serum and 24 hour&#xD;
      urine specimens. &quot;Progressive disease&quot; (PD) will require a consecutive confirmatory&#xD;
      measurement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>All patients receive PId. Patients showing a biochemical relapse receive PICd afterwards, while patients showing a clinical relapse go off study.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response rate (PId) according to the IMWG criteria.</measure>
    <time_frame>1 year throughout study completion</time_frame>
    <description>Overall response rate at PId</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>1 year throughout study completion</time_frame>
    <description>Disease control rate in patients receiving PId (at least SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>1 year throughout study completion</time_frame>
    <description>Overall response rate (PR or better) for patients intensified with PICd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate in patients intensified with PICd (at least SD)</measure>
    <time_frame>1 year throughout study completion</time_frame>
    <description>Disease control rate in patients intensified with PICd (at least SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>1 year throughout study completion</time_frame>
    <description>Progression-free survival (PFS) for patients receiving PId and for patients receiving PICd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year throughout study completion</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subsequent anti-myeloma regimens (including best response)</measure>
    <time_frame>1 year throughout study completion</time_frame>
    <description>Best response during induction by PId</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Molecular cytogenetics by FISH analysis</measure>
    <time_frame>1 year throughout study completion</time_frame>
    <description>Evaluation of molecular cytogenetic abnormalities</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety of the dosing regimens and relationship of AEs</measure>
    <time_frame>1 year throughout study completion</time_frame>
    <description>Incidence, severity and relationship of AEs/SAEs of the dosing regimens (safety measures)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>PId</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of eligible patients with combination of Pomalidomide, Ixazomib, Dexamethasone for all patients until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PICd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of patients showing an isolated biochemical relapse at disease progression with combination of Pomalidomide, Ixazomib, Dexamethasone plus Cyclophosphamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN9708</intervention_name>
    <description>Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle</description>
    <arm_group_label>PICd</arm_group_label>
    <arm_group_label>PId</arm_group_label>
    <other_name>Ixazomib 4.0 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide 4 MG Oral Capsule</intervention_name>
    <description>Study drug will be given as an oral dose of 4.0 mg on day 1 until day 21, followed by 1 week without study drug in a 28-day cycle.</description>
    <arm_group_label>PICd</arm_group_label>
    <arm_group_label>PId</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be administered as a single, oral dose of 40 mg/day weekly on day 1, 8, 15 and 22 in patients from 18 to 74 years old. For patients ≥ 75 years old dose has to be reduced to 20 mg/day with the same treatment schedule.</description>
    <arm_group_label>PICd</arm_group_label>
    <arm_group_label>PId</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide will be administered once daily as an oral dose of 50 mg on cycle days 1 to 21, followed by one week without drug in a 28-day cycle.</description>
    <arm_group_label>PICd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male or female patients ≥ 18 years of age at the time of signing the informed consent&#xD;
             form&#xD;
&#xD;
          -  Patients capable to understand the purposes and risks of the study, who are willing&#xD;
             and able to participate in the study and from whom written and dated informed consent&#xD;
             to participate in the study has been obtained prior to any study related assessments/&#xD;
             procedures being conducted&#xD;
&#xD;
          -  Patients with relapsed or refractory, histologically confirmed multiple myeloma&#xD;
&#xD;
          -  Patients must have received at least two but not more than four prior anti-myeloma&#xD;
             regimens including lenalidomide and bortezomib and have demonstrated disease&#xD;
             progression on the last therapy&#xD;
&#xD;
          -  Prior treatments must have included both lenalidomide and bortezomib: at least two&#xD;
             consecutive cycles of lenalidomide and bortezomib (alone or in combination) and&#xD;
             adequate prior alkylator exposure. This is either as part of a stem cell transplant or&#xD;
             at least 6 consecutive cycles of an alkylator-based therapy.&#xD;
&#xD;
          -  Patients must have failed bortezomib and lenalidomide therapy: progression within 60&#xD;
             days; PR or better with progression within 6 month and/or bortezomib intolerant after&#xD;
             ≥ 2 cycles and achieving ≤ MR&#xD;
&#xD;
          -  Relapsed from or refractory to at least one regimen (induction, autologous stem cell&#xD;
             transplantation (or allogenic stem cell transplantation) and consolidation/maintenance&#xD;
             are considered one &quot;regimen&quot;)&#xD;
&#xD;
          -  Measurable levels of serum and/or urine M-protein: serum M-protein ≥ 5 g/L and/or&#xD;
             urine M-protein ≥ 200 mg/24h or serum free light chain (sFLC) concentration of &gt; 100&#xD;
             mg/L of the involved FLC, provided sFLC ratio is abnormal (sFLC K/λ ratio (&lt; 0.26 or &gt;&#xD;
             1.65)&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2&#xD;
&#xD;
          -  Patients must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
          -  All women and men must acknowledge to have understood the hazards and necessary&#xD;
             precautions associated with the use of pomalidomide and ixazomib&#xD;
&#xD;
          -  All subjects must agree in writing to strictly adhere to the Pomalidomide Pregnancy&#xD;
             Prevention Plan as given in Appendix C&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) must:&#xD;
&#xD;
          -  Understand the potential teratogenic risk to the unborn child&#xD;
&#xD;
          -  Agree to utilize two reliable forms of contraception simultaneously without&#xD;
             interruption for at least 28 days before starting study drug, while participating in&#xD;
             the study (including dose interruptions), and for at least 90 days after study&#xD;
             treatment discontinuation&#xD;
&#xD;
          -  Be capable of complying with effective contraceptive measures&#xD;
&#xD;
          -  Be informed and understand the potential consequences of pregnancy and the need to&#xD;
             notify her study doctor immediately if there is a risk of pregnancy&#xD;
&#xD;
          -  Understand the need to commence the study treatment as soon as study drug is dispensed&#xD;
             following a negative pregnancy test&#xD;
&#xD;
          -  Understand the need and accept to undergo pregnancy testing based on the frequency&#xD;
             outlined in this protocol&#xD;
&#xD;
          -  Females must agree to abstain from breastfeeding during study participation and for at&#xD;
             least 28 days after study drug discontinuation&#xD;
&#xD;
          -  Males must agree to use a latex condom during any sexual contact with FCBP while&#xD;
             participating in the study and for 90 days following discontinuation from this study,&#xD;
             even if he has undergone a successful vasectomy&#xD;
&#xD;
          -  Males must also agree to refrain from donating semen or sperm while on the study drugs&#xD;
             and for 90 days after discontinuation from this study treatment&#xD;
&#xD;
          -  Subjects must agree to refrain from donating blood while on study therapy and for 28&#xD;
             days after discontinuation from this study treatment&#xD;
&#xD;
          -  Subjects must agree not to share medication&#xD;
&#xD;
          -  Patients must meet the following clinical laboratory criteria:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) 1 x 109/L&#xD;
&#xD;
          -  Platelet count 75 x 109/L for patients in whom &lt; 50% of bone marrow nucleated cells&#xD;
             are plasma cells&#xD;
&#xD;
          -  Platelet count ≥ 30 x 109/L for patients in whom ≥ 50% of bone marrow nucleated cells&#xD;
             are plasma cells. (Platelet transfusions to help patients meet eligibility criteria&#xD;
             are not allowed within 3 days before study enrollment)&#xD;
&#xD;
          -  Total bilirubin 1.5 the upper limit of the normal range (ULN)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 ULN&#xD;
&#xD;
          -  Calculated creatinine clearance 30 mL/min&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Concomitant cancer chemo- or radiotherapy (except for local radiation therapy for&#xD;
             preexisting lytic lesions)&#xD;
&#xD;
          -  Treatment with any investigational product within 60 days prior to first&#xD;
             administration of pomalidomide and ixazomib&#xD;
&#xD;
          -  Patients eligible for autologous and / or allogeneic stem cell transplantation&#xD;
&#xD;
          -  Abnormal/inadequate organ or bone marrow function as defined below (any single&#xD;
             parameter to fulfill condition): ANC &lt; 1 x 109/L&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 g/dL (prior RBC transfusion or recombinant human erythropoietin use&#xD;
             is permitted)&#xD;
&#xD;
          -  Platelet count &lt; 75 x 109/L for patients in whom &lt; 50% of bone marrow nucleated cells&#xD;
             are plasma cells&#xD;
&#xD;
          -  Platelet count &lt; 30 x 109/L for patients in whom ≥ 50% of bone marrow nucleated cells&#xD;
             are plasma cells&#xD;
&#xD;
          -  Estimated GFR (MDRD) &lt; 45 ml/min&#xD;
&#xD;
          -  AST/ALT &gt; 3 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum (total) bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          -  Corrected serum calcium &gt; 14 mg/dL (&gt; 3.5 mmol/L); or free ionized calcium &gt; 6.5 mg/dL&#xD;
             (&gt; 1.6 mmol/L)&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 x ULN&#xD;
&#xD;
          -  Prior pomalidomide based therapy&#xD;
&#xD;
          -  Prior ixazomib based therapy&#xD;
&#xD;
          -  Baseline peripheral neuropathy &gt; Grade 1 on clinical examination within 14 days before&#xD;
             enrollment&#xD;
&#xD;
          -  Active HIV, hepatitis B (including patients who are tested Anti-HBc-positive and / or&#xD;
             HBsAg-positive) or hepatitis C infection after serologic testing&#xD;
&#xD;
          -  Any other concurrent disease or medical conditions that are deemed to interfere with&#xD;
             the conduct of the study as judged by the investigator&#xD;
&#xD;
          -  Known hypersensitivity to pomalidomide and its analogues in general and/or to ixazomib&#xD;
             and its analogues or to any other component of study drugs&#xD;
&#xD;
          -  Prior malignancy excluding adequately treated with curative intent basal cell or&#xD;
             squamous cell skin cancer, in situ cervical, breast or prostate cancer without any&#xD;
             evidence of residual disease or requiring anti-cancer treatment &lt; 2 years prior to&#xD;
             initiating study treatment&#xD;
&#xD;
          -  Patients with congestive heart failure NYHA Class III and IV, cardiac arrhythmias&#xD;
             (except atrioventricular block type I and II, atrial fibrillation/flutter, bundle&#xD;
             brunch block) or other signs and symptoms of relevant cardiovascular disease&#xD;
&#xD;
          -  Pregnant women, nursing mothers, lactating women, and women of childbearing potential&#xD;
             as well as male subjects who are unwilling to adhere to the guidelines of the&#xD;
             treatment-specific pregnancy prevention program&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin,&#xD;
             ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin,&#xD;
             itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A&#xD;
             inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital),&#xD;
             or use of Ginkgo biloba or St. John's wort within 14 days before randomization in the&#xD;
             study&#xD;
&#xD;
          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral&#xD;
             absorption or tolerance of the study drugs including difficulty swallowing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Knop, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Würzburg / Medizinische Klinik und Poliklinik II</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Puttrich</last_name>
    <phone>+49 351 25933</phone>
    <phone_ext>193</phone_ext>
    <email>martin.puttrich@g-wt.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München / III. Med. Klinik und Poliklinik</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Bassermann, Prof. Dr. med.</last_name>
      <email>florian.bassermann@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>phase drei Hämato-Onkologischer Studienkreis am Klinikum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Welslau, Dr.med.</last_name>
      <email>info@onkologie-ab.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg / Klinik am Bruderwald, Zentrum für Innere Medizin, Med. Klinik V, Hämatologie und internistische Onkologie</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Seggewiß-Bernhardt, PD.Dr. med.</last_name>
      <email>ruth.seggewiss-bernhardt@sozialstiftung-bamberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt am main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivana von Metzler, Dr. med.</last_name>
      <email>ivana.metzler@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena / Klinik für Innere Medizin II, Abteilung für Hämatologie und internistische Onkologie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie von Lilienfeld-Toal, Prof. Dr. med.</last_name>
      <email>marie.von_lilienfeld-toal@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg A.Ö.R / Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Wolleschak, Dr. med.</last_name>
      <email>denise.wolleschak@med.ovgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Ostalb Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Hebart, Prof. Dr. med.</last_name>
      <email>holger.hebart@kliniken-ostalb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster / Medizinische Klinik A</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Reusch, Dr. med.</last_name>
      <email>julia.reusch@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Dechow, Prof. Dr. med.</last_name>
      <email>dechow@onkonet.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm / Klinik für Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Kull, Dr. med.</last_name>
      <email>miriam.kull@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Knop, Prof.</last_name>
      <email>Knop_S@ukw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

